Ohio Leukemia Researchers Led by OSU CCC—James’ Secure $9.1m from NCI

Ohio Leukemia Researchers Led by OSU CCC—James’ Secure $9.1m from NCI

The Ohio State University Comprehensive Cancer Center—Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC—James) and the Ohio State University College of Veterinary Medicine (CVM) were awarded a five-year, $9.1 million grant Program Project Grant (PPG) renewal from the National Cancer Institute, part of the National Institutes of Health (NIH).

This ongoing study was first founded in 2003, and its continuation offers OSUCCC-James, CVM, and collaborators at the Washington University—St. Louis Siteman Cancer Center the ability to continue investigating retrovirus models of cancer.

The Goal of the Research

This particular PPG is funded ongoing to support the mission of using a human T-cell leukemia virus type (HTLV-1) T-cell immortalization model in an effort to better understand the microenvironmental, cellular, and viral elements associated with adult T-cell (ATL) leukemia.

Patrick Green, PhD, associate director for basic research at the OSUCCC—James and director of the Center for Retrovirus Research at the CVM commented, “this is a powerful area of basic research we expect to result in new targets for the treatment of HTLV-1 infection, ATL, and related leukemias and lymphomas.”

Lead Research/Investigator

Patrick Green, PhD, associate director for basic research at the OSUCCC—James and director of the Center for Retrovirus Research at the CVM, professor, associate dean for research and graduate studies, CVM, Robert H Rainer Chair in Industrial Veterinary Medicine and Research